Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Atara Biotherapeutics Inc ATRA

Healthcare Biotechnology
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel... see more

Recent & Breaking News (NDAQ:ATRA)

Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference

Business Wire 8 days ago

Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress

Business Wire 9 days ago

Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Business Wire November 5, 2024

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 4, 2024

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 6, 2024

Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Business Wire September 4, 2024

Atara Biotherapeutics Announces $36 Million Registered Direct Offering

Business Wire September 3, 2024

Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update

Business Wire August 12, 2024

Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference

Business Wire August 7, 2024

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Business Wire July 17, 2024

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire July 5, 2024

Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum

Business Wire July 3, 2024

Atara Biotherapeutics' Ebvallo(TM) (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases

Business Wire June 21, 2024

Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split

Business Wire June 17, 2024

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 7, 2024

Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Business Wire June 5, 2024

Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting

Business Wire May 29, 2024

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

Business Wire May 20, 2024

Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress

Business Wire May 9, 2024

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire May 3, 2024